Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

536.00 -6.04 (-1.11%)
Streaming Delayed Price Updated: 2:37 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results this Monday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Market-Beating Stocks to Consider Right Now
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
News headline image
1 Volatile Stock with Solid Fundamentals and 2 We Avoid
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Topics Economy Supply Chain
News headline image
2 Cash-Heavy Stocks with Promising Prospects and 1 We Find Risky
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
News headline image
Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?
What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, reaching $617.27 per share. This was partly due to its solid quarterly... 
Via StockStory
Topics Supply Chain
News headline image
2 Healthcare Stocks to Keep an Eye On and 1 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only... 
Via StockStory
Topics Stocks
News headline image
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026
From Medpace Holdings, Inc.
Via Business Wire
News headline image
1 Mid-Cap Stock with Competitive Advantages and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
2 Profitable Stocks to Keep an Eye On and 1 We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
1 Volatile Stock to Target This Week and 2 We Turn Down
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
News headline image
Medpace (MEDP) Q3 2025 Earnings Call Transcript ↗
Medpace (MEDP) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Medpace (NASDAQ:MEDP): Strongest Q3 Results from the Drug Development Inputs & Services Group
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
News headline image
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government... 
Via StockStory
Topics Economy Government
News headline image
MEDPACE HOLDINGS INC (NASDAQ:MEDP) Shows Strong Growth and Momentum Alignment ↗
MEDP stock shows strong technical momentum and accelerating earnings growth, fitting a proven strategy for finding leading growth stocks. 
Via Chartmill
News headline image
6 Healthcare Stocks With Strong Upward Momentum ↗
 
Via Benzinga
News headline image
2 Mooning Stocks to Research Further and 1 We Question
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
Topics Economy
News headline image
Drug Development Inputs & Services Stocks Q3 Results: Benchmarking UFP Technologies (NASDAQ:UFPT)
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including UFP Technologies (NASDAQ:UFPT) and its peers. 
Via StockStory
News headline image
Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its... 
Via StockStory
News headline image
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers. 
Via StockStory
News headline image
1 Mid-Cap Stock to Target This Week and 2 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
3 Cash-Heavy Stocks Worth Your Attention
In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and... 
Via StockStory
News headline image
5 Revealing Analyst Questions From Medpace’s Q3 Earnings Call
Medpace’s third quarter results were well received by the market, driven by broad-based revenue growth and robust net new business awards. Management credited strong demand across therapeutic... 
Via StockStory
Topics Earnings
News headline image
8 Analysts Assess Medpace Hldgs: What You Need To Know ↗
 
Via Benzinga
News headline image
Medpace Soars: AI and Data Analytics Propel Clinical Trial Giant to Record Heights
Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global contract research organization (CRO), has been experiencing an unprecedented surge in its stock value, reaching an all-time high of $543.90 on... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Why Medpace Popped 13% This Week ↗
The biopharmaceutical processor posted another strong earnings result for the third quarter. 
Via The Motley Fool
News headline image
Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings ↗
 
Via Benzinga
News headline image
MEDP Q3 Deep Dive: Broad-Based Growth and Strong Pipeline Fuel Upbeat Outlook
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 23.7% year on year to $659.9 million. The company’s full-year... 
Via StockStory
News headline image
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins ↗
Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance. 
Via Benzinga
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.